康臣药业(01681)附属公司认购理财产品

Core Viewpoint - 康臣药业 has made significant investments in financial products through its subsidiaries, indicating a strategic use of idle funds to enhance financial returns [1] Group 1: Investment Details - 康臣药业's subsidiary, 霍尔果斯康臣, subscribed to a financial product from 浦发银行 with a principal amount of RMB 252 million [1] - On August 4, 2025, 霍尔果斯康臣, 玉林制药, and 内蒙古康臣 collectively subscribed to several financial products from 浦银理财, totaling a principal amount of RMB 623.5 million [1] - The group utilized its idle funds to make these subscriptions, reflecting a proactive approach to capital management [1]